ArcherDx

The team performed anchored multiplex PCR-based next-generation sequencing on 26 genes linked to sarcomas, comparing the method to standard diagnostic tools.

The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.

The researchers plan to use ArcherDX's technology to evaluate minimal residual disease in pediatric AML patients participating in a clinical trial.

Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.

The company intends to use the funds to support the commercial growth of its targeted sequencing assays.

The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software. 

The firm has inked a number of significant deals over the past year and presented research involving new assays at last week's American Molecular Pathology meeting.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.